Xiao Ding

Research interests

Publications

• Microglial NLRP3 inflammasome activates neurotoxic astrocytes in depression-like mice

  Cell Reports · 2022 · https://doi.org/10.1016/j.celrep.2022.111532

• Biological Function and Stress Response Mechanism of MYB Transcription Factor Family Genes

  Journal of Plant Growth Regulation · 2022 · 10.1007/s00344-021-10557-2

• CRISPR/Cas Genome Editing Technologies for Plant Improvement against Biotic and Abiotic Stresses: Advances, Limitations, and Future Perspectives

  Cells · 2022 · 10.3390/cells11233928

• Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China

  Cell Host & Microbe · 2020 · https://doi.org/10.1016/j.chom.2020.02.001

• CRISPR/Cas Systems in Genome Editing: Methodologies and Tools for sgRNA Design, Off‐Target Evaluation, and Strategies to Mitigate Off‐Target Effects

  Advanced Science · 2020 · 10.1002/advs.201902312

• Preliminary study to identify severe from moderate cases of COVID-19 using combined hematology parameters

  Annals of Translational Medicine · 2020 · https://doi.org/10.21037/atm-20-3391

• Pyridoxine induces glutathione synthesis via PKM2-mediated Nrf2 transactivation and confers neuroprotection

  Nature Communications · 2020 · https://doi.org/10.1038/s41467-020-14788-x

• Fecal microbiota transplantation: A promising treatment for radiation enteritis?

  Radiotherapy and Oncology · 2020 · https://doi.org/10.1016/j.radonc.2020.01.011

• Febrile Temperature Critically Controls the Differentiation and Pathogenicity of T Helper 17 Cells

  Immunity · 2020 · 10.1016/j.immuni.2020.01.006

• The application of a heat‐inducible CRISPR/Cas12b (C2c1) genome editing system in tetraploid cotton (G. hirsutum) plants

  Plant Biotechnology Journal · 2020 · 10.1111/pbi.13417

• Robust CRISPR/Cpf1 (Cas12a)‐mediated genome editing in allotetraploid cotton (Gossypium hirsutum)

  Plant Biotechnology Journal · 2019 · 10.1111/pbi.13147

• Long-Term Safety and Efficacy of Fecal Microbiota Transplant in Active Ulcerative Colitis

  Drug Safety · 2019 · https://doi.org/10.1007/s40264-019-00809-2

• Improving CRISPR-Cas9 Genome Editing Efficiency by Fusion with Chromatin-Modulating Peptides

  The CRISPR Journal · 2019 · 10.1089/crispr.2018.0036

• High‐efficient and precise base editing of C•G to T•A in the allotetraploid cotton (Gossypium hirsutum) genome using a modified CRISPR /Cas9 system

  Plant Biotechnology Journal · 2019 · https://doi.org/10.1111/pbi.13168

• Evaluation of different 16S rRNA gene V regions for exploring bacterial diversity in a eutrophic freshwater lake

  The Science of The Total Environment · 2017 · https://doi.org/10.1016/j.scitotenv.2017.09.228

• Targeted activation of diverse CRISPR-Cas systems for mammalian genome editing via proximal CRISPR targeting

  Nature Communications · 2017 · https://doi.org/10.1038/ncomms14958

• Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir

  Gastroenterology · 2016 · https://doi.org/10.1053/j.gastro.2016.06.002

• Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis

  Hepatology · 2015 · 10.1002/hep.27826

• Concordance of sustained virological response 4, 12, and 24 weeks post‐treatment with sofosbuvir‐containing regimens for hepatitis C virus

  Hepatology · 2014 · https://doi.org/10.1002/hep.27366

• Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection

  New England Journal of Medicine · 2014 · https://doi.org/10.1056/nejmoa1402454

• Rare earth elements activate endocytosis in plant cells

  Proceedings of the National Academy of Sciences · 2014 · https://doi.org/10.1073/pnas.1413376111

• Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C

  New England Journal of Medicine · 2013 · https://doi.org/10.1056/nejmoa1208953

• Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial

  The Lancet · 2013 · 10.1016/s0140-6736(13)62121-2

• Efficacy of Nucleotide Polymerase Inhibitor Sofosbuvir Plus the NS5A Inhibitor Ledipasvir or the NS5B Non-Nucleoside Inhibitor GS-9669 Against HCV Genotype 1 Infection

  Gastroenterology · 2013 · https://doi.org/10.1053/j.gastro.2013.11.007

• Carbon monoxide alleviates cadmium‐induced oxidative damage by modulating glutathione metabolism in the roots of Medicago sativa

  New Phytologist · 2007 · https://doi.org/10.1111/j.1469-8137.2007.02251.x

Current projects

No projects listed.